S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL

• I. Solman,
• R. Singh Mali,
• L. Scarfo,
• M. Choi,
• C. Moreno,
• A. Grigg,
• J. P. Dean,
• E. Szafer-Glusman

Affiliations

I. Solman

1 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

R. Singh Mali

2 AbbVie, North Chicago, IL, United States of America

L. Scarfo

3 Ospedale San Raffaele, Milan, Italy

M. Choi

4 University of California San Diego, San Diego, CA, United States of America

C. Moreno

5 Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona

A. Grigg

7 Austin Hospital, Heidelberg, VIC, Australia

J. P. Dean

1 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

E. Szafer-Glusman

1 Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA